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Two monomeric 32-kDa proteins, termed 32K-I (PI 5.8) and 32K-II (pZ 5.1), were isolated from human 
placenta, which was solubilized by a Ca z +-chelator. Only 32K-I was associated with PLAz-inhibitory activ- 
ity. CNBr peptide mapping indicated that 32K-I was distinct from 32K-II and two 36-kDa proteins, called 
calpactin I and II or lipocortin II and I, which have been shown to possess PLAZ-inhibitory activity. 32K-I 
bound to PS in a Ca* +-dependent manner. 32K-I was detected in many tissues except brain, cardiac and 
skeletal muscle. 
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1. INTRODUCTION 
The actions of hormones, growth factors or on- 
cogenes evoke the acceleration of phospholipid 
turnover and the elevation of intracellular free 
Ca’ + -concentrations [ 1,2]. Calcium and phospho- 
lipids as second messengers transfer their effects 
through specific binding proteins to specific targets 
of membrane, cytoplasmic and nuclear com- 
ponents. Recent works have revealed the presence 
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of new families of Ca’+- and phospholipid-binding 
proteins distinct from protein kinase C [3-71. 
Lipocortins or calpactins which are the substrates 
of the src-gene product and EGF-receptor tyrosine 
kinases, were identified as major members of the 
family. Lipocortins were shown to inhibit PLA2 
activity [6,8,9], and were induced by steroid hor- 
mone and secreted by cells. It has been postulated 
that they may play crucial roles in controlling the 
biosynthesis of cyclooxygenase by inhibiting PLA2 
activity [lO,ll]. Because a variety of proteins 
similar to lipocortins have been detected in various 
tissues and species [12-161, it is necessary to find 
out which protein molecular masses are involved in 
anti-inflammatory functions. 
We have recently purified three distinct forms of 
36-kDa proteins with PLAz-inhibitory activity 
from human placenta which belong to the new 
family of Ca’+- and phospholipid-binding proteins 
[9]. Here we report that a 32-kDa protein purified 
from human placenta inhibits PLA2 activity in 
vitro. This protein is not a proteolytic fragment of 
calpactins or lipocortins. 
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2. MATERIALS AND METHODS 
2.1. Purification of 32K-I and 32K-II proteins 
A fresh placenta was dissected free of adjacent 
tissues and extensively washed with chilled saline 
containing 5% sucrose. All subsequent steps were 
carried out at 4°C. The washed placenta was 
homogenized in 20 mM Tris-HCl, pH 7.4, 150 mM 
NaCl supplemented with the proteinase inhibitors 
described in [9]. The homogenate was centrifuged 
for 60 min at 30000 x g and washed twice with 50 
mM Tris-HCl, pH 7.4, 1 mM CaCl2 and once with 
20 mM Hepes, pH 7.5. The resulting pellet was ex- 
tracted overnight in 20 mM Hepes, pH 7.5, con- 
taining 5 mM EGTA and subjected to a DE-52 
cellulose column (Whatman) equilibrated in 10 
mM imidazole, pH 7.4, and 0.5 mM DTT. The 
flow-through fraction was concentrated with 
Pellicon (Millipore) and applied to a hydrox- 
yapatite column (Koken, Co., Tokyo, Japan) 
equilibrated with 10 mM imidazole, pH 7.4, 0.5 
mM DTT and 10% glycerol. It was eluted in a 
linear gradient of O-O.5 M potassium phosphate 
buffer (pH 7.4) containing 1 mM EDTA. The 0.2 
M eluate was loaded on a Mono S column (Phar- 
macia) equilibrated with 20 mM sodium 
acetate/acetic acid, pH 5.6, 0.5 mM DTT, and 
then eluted in a linear gradient of O-O.5 M NaCl. 
The 0.1 M eluate containing mainly a 32-kDa 
polypeptide was purified further by gel filtration 
using a G3OOOSW HPLC column (Toyosoda) 
equilibrated with gel filtration buffer (10 mM im- 
idazole, pH 7.4, 100 mM NaCl, 1 mM EGTA, 0.5 
mM DTT). The 32-kDa polypeptide (32K-I) was 
finally purified to 95% purity (see fig. 1, lane 6). 
The DE-52-absorbed materials were eluted in a 
linear gradient of O-O.5 M NaCl. The 0.1 M eluate 
was gel filtrated on a Sephacryl S-200 column (2 x 
100 cm, Pharmacia) equilibrated with the gel filtra- 
tion buffer. Another 32-kDa polypeptide (32K-II) 
was homogeneously purified as a monomeric form 
(see fig. 1, lane 8). 
2.2. Assay for PLA2 inhibitory activity 
PLAz-inhibitory activity was conventionally 
measured as described in [ 141, using autoclaved 
[3H]oleic acid-labeled Escherichia coli as the 
substrate of PLA2, except for bee venom PLA2 
(Sigma) and the reaction buffer (10 mM imidazole, 
268 
pH 7.0, 1 mM CaC12, 2 mM MgCL, 0.02 mM 
ATP). The reaction was initiated at 30°C by addi- 
tion of 3H-labeled E. coli to the protein sample 
which was preincubated with PLA2 (50 ng) at 4°C 
for 10 min, and terminated 30 s later by addition 
of 2 N HCl and 100 mg/ml BSA. After centrifuga- 
tion, the released radioactivity in the supernatant 
was counted in a liquid scintillation counter. The 
reaction was linear under these conditions. About 
30-50% radioactivity of 3H-labeled E. coli was 
released by PLA2 (50 pg/assay). 
2.3. CNBr peptide mapping 
As described [17], the cleaved peptides of the 
proteins were analyzed by SDS-PAGE (15% gel) 
and visualized by silver staining. 
2.4. Phospholipid and F-actin binding assay 
The assay was performed as described in [9]. 
2.5. Preparation of antiserum 
New Zealand White rabbits were immunized 
with purified protein (100-200 pg per immuniza- 
tion). The animals were injected with a 1: 1 emul- 
sion of the antigen in complete Freund’s adjuvant. 
Three weeks later, two booster immunizations 
were given every 2 weeks as 1: 1 emulsion in in- 
complete Freund’s adjuvant. The antisera were 
collected 10 days following the second booster. 
2.6. Western blot analysis 
Purified proteins (1 pg each) or tissue 
homogenates were analyzed in SDS-PAGE, elec- 
trically transferred to nitrocellulose paper, and 
stained with India ink as described by Glenney 
[18]. The paper was incubated with 1: 1000-5000 
dilution of antiserum and followed by incubation 
with 1251-labeled protein A and autoradiography. 
For preparation of the tissue homogenate (20% 
v/w), tissues were homogenized in buffer (20 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, proteinase in- 
hibitors) by a Physcotron homogenizer. The 
homogenates were prerun on SDS-PAGE (12.5% 
gel) and stained with Coomassie blue. On the basis 
of stained gel, the amount of tissue protein used 
was adjusted to approximately equal. 
2.7. Isoelectric focusing 
Slab-gel isoelectric focusing was performed ac- 
cording to Giulian et al. [19]. 
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3. RESULTS AND DISCUSSION 
When the homogenate of whole human placenta 
was treated with EGTA, the major polypeptides 
detected by SDS-PAGE were of 68, 45, 36 and 32 
kDa (fig.1, lane 2). The 32-, 36- and 68-kDa pro- 
teins passed through a DE-52 column (lane 3). The 
32-kDa proteins were separated from two other 
proteins by an FPLC mono S column (lane 5). 
Finally the 32-kDa protein was homogeneously 
purified by gel filtration on HPLC (lane 6). The 
protein was monomeric and designated as 32K-I. 
Another 32-kDa protein, termed 32K-II, was 
eluted at 0.1 M NaCl from the DE-52 column (fig. 
1, lane 7) and gel-filtrated on Sephacryl S-200 to 
homogeneity (lane 8). The isoelectric points of 
32K-I and -11 were 5.8 and 5.1, respectively. 
In vitro phospholipid-binding experiments 
showed that 32K-I bound to PS but not to 
phosphatidylinositol and phosphatidylcholine at 
50~M of free Ca2+ (not.shown). This binding was 
blocked by EGTA. In contrast to 32K-I, no 
phospholipid-binding was observed with 32K-II. 
1’234 56 7 8 
Fig.1. SDS-PAGE of 32-kDa proteins from human 
placenta at each purification step. Two monomeric 
32-kDa proteins were purified as described in section 2. 
The homogenate of whole human placenta (lane l), the 
extract of the homogenate with 5 mM EGTA (lane 2), 
the concentrated flow-through fraction of the EGTA ex- 
tract applied to a DE-52 column (lane 3), the 0.2 M 
potassium phosphate eluate from a hydroxyapatite col- 
umn (lane 4), the 0.1 M NaCl eluate from a Mono S col- 
umn (lane 5), purified 32K-I after gel filtration (lane 6), 
the 0.1 M NaCl eluate from a DE-52 column (lane 7) and 
purified 32K-II after gel filtration on a Sephacryl S-200 
column (lane 8). The numbers on the left side represent 
the molecular mass x lo-‘. The arrowhead on the right 
indicates 32K-I and -11. Note that faint bands seen in all 
OOW+- 
E. coli (25000 cpm) as substrate to aliquots of 
purified proteins preincubated with PLAz (50 ng) at 4°C 
for 10 min, and terminated 30 s later. The released 
radioactivity from the E. coli membrane was counted in 
a liquid scintillation counter. In all analyses, samples 
were assayed in duplicates and adjusted for nonspecific 
release by subtracting a control value. 32K-I (0) and 
lanes near 68 kDa were artificial. 32K-II (0). 
Neither 32K-I nor 32K-II showed F-actin- 
binding ability in the presence of 0.1 M KCl. 
Whereas they bound to F-actin in a 
Ca’+-dependent manner in the absence of 0.1 M 
KCl. We do not know yet whether 32K-I and -11 
are potassium-sensitive F-actin-binding proteins. 
The PLAz-inhibitory activity was examined for 
32K-I and -11. As shown in fig.2, only 32K-I show- 
ed a dose-dependent PLAz-inhibitory activity. 
Almost indentical results were obtained when dif- 
ferent assay conditions [9] were employed. The 
magnitude of the PLAz-inhibitory activity of 32K-I 
appeared to be 2-fold lower than that of calpactins 
(not shown).. 
We have recently reported [9] that three distinct 
forms of 36-kDa proteins purified from the mem- 
branes and the total human placenta homogenate 
showed PLAz-inhibitory activity as well as 
Ca2+-dependent phospholipid- and F-actin- 
binding abilities. We identified the 36-kDa pro- 
teins as human calpactins or lipocortins [7-91. 
32K-I was copurified with the 36-kDa proteins un- 
til further purification using a hydroxyapatite col- 
umn (see fig. 1, lanes 3 and 4; [9]). Therefore, we 
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Fig.3. Comparison of CNBr peptide maps between 
32-kDa proteins and calpactins. Purified proteins (10 fig 
each) were separated on SDS-PAGE (15% gel). Each 
band that stained with Coomassie blue was excised from 
the gel, incubated with CNBr (60 mg/ml) at 20°C for 2 
h and washed. CNBr-cleaved fragments were visualized 
by silver staining after electrophoresis on an SDS-PAG 
(15%) containing 8 M urea. In panel A, 32K-I (lane 1); 
32K-II (lane 2); calpactin I (36K-I)(lane 3); and calpactin 
II (36K-II)(lane 4). In panel B, calpactin II (lane, 1); 
calpactin II-related, Ca’+-dependent phospholipid- 
binding 6%kDa protein specific for human placenta 
(68K-I)(lane 2); another Ca’+-dependent phospholipid- 
binding 68-kDa from human placenta (68K-II)(lane 3). 
compared the structure among 32K-I, 32K-II and 
calpactins. CNBr peptide mapping analysis in- 
dicated that 32K-I was distinct from 32K-II, 
calpactin I, II and 68-kDa proteins (fig.3). 
However, this result does not rule out the possibili- 
ty that they possess common epitopes. 
To investigate the immunological relationships 
among these proteins, rabbit antibodies against he 
purified proteins were prepared and then their 
cross-reactivities were examined by Western blot- 
ting (fig.4). Anti-32K-I antibody cross-reacted 
weakly with 32K-II and 68K-II. It also detected 
36K-I (calpactin I) at a level lo-fold lower. 
Anti-32K-II antibody reacted strongly with 32K-I 
and weakly with 68K-II. 32K-I and -11 were reac- 
tive with anti-68K-II antibody. Antisera against 
calpactins were not able to react with 32K-I, 32K-II 
and 68K-II. These results suggest he presence of 
common antigenic determinant(s) in 32K-I, -11 and 
68K-II even though their CNBr peptide maps were 
different. 
The 68-kDa protein in the human placenta 
homogenate recognized by the anti-32K-II an- 
tibody but not by anti-68K-I and -11 antibodies will 
require further investigation (fig.4B, lane 1). The 
purification and characterization of 68K-I which 
cross-reacted with the anti-calpactin II antibody 
will be published elsewhere (in preparation). 
The tissue-distribution of 32K-I or 32K-II in 
adult rat was examined by using the Western blot- 
ting method. The results are summarized in table 
1. 32K-I was expressed in many tissues except car- 
diac muscle, skeletal muscle and brain. The 
distribution of 32K-I is similar to that of protein 
II, porcine intestinal Ca’+-dependent phospholi- 
pid-binding 32-kDa protein [7,20-221. Since 32K-I 
has similar properties to protein II including PS- 
binding, 32K-I may be a human homologue of pro- 
tein II. Weber and co-workers [7] have recently 
reported that protein II is a member of a multigene 
family including calpactins or lipocortins because 
of the presence of a consensus equence of Ca2+- 
and phospholipid-binding sites [3-71. Interesting- 
ly, 32K-I was found in liver, where calpactins were 
undetectable. Endonexin (p32.5), a mammalian 
Ca2+-binding protein related to Torpedo calelec- 
trin [3,23,24] is also located in liver and has a pZ 
value and a molecular mass similar to 32K-I. To 
elucidate the relationships among these proteins, it 
will be necessary to define their chemical struc- 
tures .
Fig.4. Immunological cross-reactivity of 32K-I with antisera against 32K-II, calpactins and 68-kDa proteins. Samples 
(1 pg of each purified proteins and 1 pg of human placenta homogenate (20%, v/w)) were separated on SDS-PAGE 
(12.5%), transferred to nitrocellulose paper, reached with 1:5000 dilution of rabbit antisera, incubated with ‘2’I-protein 
A and visualized by autoradiography. Rabbit antisera were anti-32K-I (A), anti-32K-II (B), anti-calpactin I (C), anti- 
calpactin II (D), anti-68K-I (E) and anti-68K-II (F). Human placenta homogenate (lane 1), 32K-I (lane 2), 32K-II (lane 
3), calpactin I (lane 4), calpactin II (lane 5), 68K-I (lane 6) and 68K-II (lane 7). Arrowheads indicate 32-kDa, 36-kDa 
(calpactins) and 68-kDa proteins, respectively. 
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Table 1 
Distribution of 32K-I and -II proteins in adult rat* 
November 1987 
Proteins 
Tissue 
. 
32K-I 32K-II 36K-Ib 36K-IIb 68K-IC 68K-IIC 
Lung 
Intestine 
Liver 
Spleen 
Kidney 
Cardiac muscle 
Aorta 
Skeletal muscle 
Brain 
++ ++ +++ +++ - +++ 
++ ++ ++ + - +++ 
+ - _ - - + 
+ - + ++ - + 
+ + - + - ++ 
- - - _ - + 
+ + ++ ++ - +++ 
- - _ - - + 
- - - - - + 
a The preparation of tissue homogenates i  described in section 2. Approximately equal amounts of tissue 
proteins were used for Western blot analysis using rabbit antisera against indicated proteins as exactly 
described in the legend of fig.4. After incubation of the blots with “‘I-protein A, autoradiographs were 
done with short (3 h) and long (3 days) exposure time. Presence at high (+ + +), medium (+ +) or low 
(+) levels or absence (-) of the proteins was judged from the autoradiogram 
b 36K-I and -11 correspond to calpactin I and II, respectively (see [9]) 
’ 68K-I and -11 are Ca’+-dependent phospholipid-binding proteins isolated from human placenta (in 
preparation) 
fA)l23456? (B) 1 2 3 4 5 8 7 
(E) 123 4 667 (F) 1 2 3 4 5 8 7 
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